| Trial ID # | NCT04739800; NRG-GY023 |
| Phase | II |
| Drug Class | DNA Damage Repair Pathway Inhibitors: PARP |
| Drug Name | Olaparib |
| Alternate Drug Names | AZD2281, Lynparza |
| Drugs in Trial | Cediranib, Durvalumab, Liposomal doxorubicin, Olaparib, Paclitaxel, Topotecan |
| Eligible Participant | Platinum resistant ovarian cancer with 2- 5 prior therapies; all patients must have had prior bevacizumab |
| Patients Enrolled | 153 |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Randomized |
| Endpoints | ORR, PFS, OS, evaluated per RECIST |
| Efficacy | Ola+Ced+Dur (n=44) vs TPC (Pac, PLD, or Top, n=23): PFS: 2.9 vs 4.3 months, HR: 1.142 (0.60-2.18, p=0.55) |
| Conclusion | The non-chemo triplet of olaparib, cediranib and durvalumab does not improve PFS compared to standard chemotherapy |
| Reference | Lee J-M et al. Randomized phase II trial of durvalumab in combination with olaparib and cediranib (DOC) compared to olaparib and cediranib (OC) or durvalumab and cediranib (DC) or standard of care chemotherapy (SOC) in platinum-resistant ovarian cancer with prior bevacizumab (NRG-GY023). Ann Oncol (2023) 34(2) abstract 746MO |